Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

Today’s #googledoodle honors Dr. Rene Favaloro, a medical pioneer responsible for introducing #coronary #bypass surgery into the clinical field. Today would be his 96th birthday.

Congratulations to our client, @OsivaxVaccines for closing a EUR 8 million financing round to develop universal #fluvaccines & expand their oligoDOM® tech platform. To learn more about this #clinicalstage #biotech, read the press release here: https://t.co/sEHkUJhbdv

Congratulations to our client, @OsivaxVaccines for closing a EUR 8 million financing round to develop universal #fluvaccines & expand their oligoDOM® tech platform. To learn more about this #clinicalstage #biotech, read the press release here: https://t.co/sEHkUJhbdv
Osivax@OsivaxVaccines

Today we announced that we closed a Series A financing round, securing EUR 8 million in order to develop universal flu vaccines while expanding our oligoDOM® technology platform. Click here to read our entire press release: https://t.co/17PWKM3Ow0

Congratulations to our client, @BioNTech_Group who announced securing a $325M #SeriesB round, closing one of the largest private #financing rounds for a #European #biotech to advance their #individualized #cancer therapy pipelines. Read more here: https://t.co/D3fpEWcteO

Congratulations to our client, @BioNTech_Group who announced securing a $325M #SeriesB round, closing one of the largest private #financing rounds for a #European #biotech to advance their #individualized #cancer therapy pipelines. Read more here: https://t.co/D3fpEWcteO
BioNTech@BioNTech_Group

We are excited to announce the closing of a $325M #SeriesB round, one of the largest private #financing events for a #European #biotech company to advance our #individualized #cancer medicine pipeline. #DigitalTransformation #AI See full press release here:https://t.co/968cll2GPU

Load More...